Home Daily Intelligence Tracker
    • Plans Blog Contact
    Cell Source, Inc. logo
    CLCS

    Cell Source, Inc.

    MaveScore 33 Low model confidence
    Last Price US$0.95 As of Jul 10, 2026
    Market Cap US$42.8m Company size context
    7D Performance 2.15% Past 7 days
    1Y Performance 227.59% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2025

    467 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 33 Low confidence

    Stored data quality

    Freshness and coverage checks

    14/16 Partial or delayed snapshot

    Quality

    12/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    4/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    12/15 Strong

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Cell Source, Inc. Overview

    Industry: Biotechnology

    Sector: Healthcare

    Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune response Read More

    Cell Source, Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Cell Source, Inc.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-K Apr 07, 2026 SEC filing 10-Q filing Nov 14, 2024 SEC filing 10-Q filing Aug 19, 2024 SEC filing 10-Q filing Jul 29, 2024 SEC filing 10-K filing Jun 24, 2024 SEC filing 10-Q filing Nov 09, 2023 SEC filing 10-Q filing Sep 19, 2023

    Recent News



    Earnings Per Share

    Score 3.00/5
    Cell Source, Inc. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.77/5
    Cell Source, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Cell Source,... CLCS US$42.8m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 2.21/5
    Cell Source, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Cell Source,... CLCS US$42.8m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.00/5
    Cell Source, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Cell Source,... CLCS US$42.8m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Cell Source, Inc. logo

    Cell Source, Inc.

    US$0.95

    US$42.8m

    2.15%

    227.59%